Neutre
Johnson & Johnson agrees to $5.5 billion settlement over talc-related cancer claims.
Ce briefing n’est pas encore disponible dans cette langue — version anglaise affichée.
Johnson & Johnson has agreed to a $5.5 billion settlement to resolve approximately 69,000 lawsuits alleging that its talc-based products caused ovarian cancer. This settlement aims to efficiently conclude a prolonged legal battle that has been ongoing for over a decade.
Points clés
- The $5.5 billion settlement is intended to resolve about 99.75% of the remaining talc-related claims.
- Johnson & Johnson maintains that its talc products are safe and do not contain asbestos.
- The company discontinued the sale of talc-based baby powder in the U.S. in 2020, transitioning to a cornstarch-based alternative.
Sources
- Johnson & Johnson announces $5.5 billion settlement of talc lawsuitsMarketScreener Canada · July 27, 2026
- J&J to Pay $5.5 Billion to Settle Talc-Related Cancer ClaimsBloomberg Law · July 28, 2026
- Johnson & Johnson to Pay $5.5 Billion to Resolve Talc-Related Cancer ClaimsBloomberg Law · July 28, 2026
- Johnson & Johnson announces $5.5 billion settlement of talc lawsuitsMarketScreener Canada · July 27, 2026
Généré par IA à partir de sources d'actualités publiques. Ceci n'est pas un conseil financier.
